TRANSITION THERAPEUTICS
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine.
TRANSITION THERAPEUTICS
Industry:
Biopharma Biotechnology Therapeutics
Founded:
1987-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.transitiontherapeutics.com
Total Employee:
11+
Status:
Closed
Contact:
416-260-7770
Total Funding:
41.8 M USD
Technology used in webpage:
SPF Network Solutions DNS AppRiver
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Ocera Therapeutics
Ocera Therapeutics is a biopharmaceutical company developing novel therapeutics for patients with acute and chronic liver diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Vigeo Therapeutics
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors.
Current Employees Featured
Bruce Connop Vice President of Nonclinical & Pharmaceutical Development @ Transition Therapeutics
Vice President of Nonclinical & Pharmaceutical Development
2006-01-01
Tony Cruz Founder & Chief Executive Officer @ Transition Therapeutics
Founder & Chief Executive Officer
1998-07-01
Founder
Stock Details
Investors List
Oracle Investment Management Inc.
Oracle Investment Management Inc. investment in Post-IPO Equity - Transition Therapeutics
Jack W. Schuler Living Trust
Jack W. Schuler Living Trust investment in Post-IPO Equity - Transition Therapeutics
Larry N. Feinberg
Larry N. Feinberg investment in Post-IPO Equity - Transition Therapeutics
Larry N. Feinberg
Larry N. Feinberg investment in Post-IPO Equity - Transition Therapeutics
Official Site Inspections
http://www.transitiontherapeutics.com
Unable to get host informations!!!
More informations about "Transition Therapeutics"
Transition Therapeutics - Crunchbase Company Profile …
Transition Therapeutics is a biopharmaceutical company developing novel therapeutics for disease indications with large markets.See details»
Transition Therapeutics, Inc. - Drug pipelines, Patents, Clinical ...
Explore Transition Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 news, and 5 literature, Disease Domain:Endocrinology and ...See details»
Transition Therapeutics Inc - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Transition Therapeutics Inc of Toronto, ON. Get the latest business insights from Dun & Bradstreet.See details»
Organization | Transition Therapeutics
Transition Therapeutics Report issue For profit Phase 1 Phase 2 Founded: Toronto Canada (1987) Status: Acquired by Opko (2016) Organization Overview First Clinical Trial 2005 …See details»
Transition Therapeutics Inc. - Toronto, Canada
Jun 22, 2009 Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005/ AZD-103 …See details»
OPKO Health Completes Acquisition of Transition Therapeutics
Aug 31, 2016 MIAMI-- (BUSINESS WIRE)-- OPKO Health, Inc. (NASDAQ: OPK), announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc. …See details»
Transition Therapeutics Shareholders Approve Acquisition by …
MIAMI-- (BUSINESS WIRE)-- OPKO Health, Inc. (Nasdaq: OPK), announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc. …See details»
Transition Therapeutics Inc - Company Profile and News
Company profile page for Transition Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Transition Therapeutics - PitchBook
Information on acquisition, funding, cap tables, investors, and executives for Transition Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Tony Cruz - Founder & Chief Executive Officer @ Transition …
Cruz is one of the founders of Transition Therapeutics and has held the position of Chief Executive Officer of Transition Therapeutics since its inception in July 1998. Dr. Cruz was a …See details»
Transition Therapeutics Inc. | Insights
Jun 30, 2016 While Opko Health Inc. now has multiple revenue-generating products across its diverse portfolio, the company is still struggling to be profitable and lacks the strong pipeline to …See details»
OPKO Health to Acquire Transition Therapeutics - Technology …
Jul 1, 2016 OPKO to gain potential first-to-market GLP-1/Glucagon dual agonist for type 2 diabetes and obesity and phase 2 drug candidate for the treatment of androgen deficiency.See details»
Emerging Drug Developer: Transition Therapeutics | Fierce Biotech
Transition Therapeutics reaches a turning point Nearly ten years after launching Transition Therapeutics, veteran entrepreneur and scientist Dr. Tony Cruz is under no illusions about his …See details»
OPKO Health to Acquire Transition Therapeutics
Jun 30, 2016 OPKO Health, Inc. and Transition Therapeutics Inc. have announced the signing of a definitive agreement under which OPKO will acquire Transition Therapeutics, a clinical stage …See details»
Transition Therapeutics Inc.: News Release
TORONTO, Feb. 22, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or "Company") (TSX:TTH) (Nasdaq:TTHI) is aware of the significant increase in its share price in …See details»
Transition Therapeutics Announces Dosing of First Patient in Phase …
Apr 25, 2016 Share this article TORONTO, April 25, 2016 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of …See details»
Transition Therapeutics Announces Top Line Phase 2 Clinical Study ...
Feb 1, 2016 Share this article TORONTO, Feb. 1, 2016 /CNW/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the results of a …See details»
Interview: Tony Cruz, Chairman and CEO, Transition Therapeutics, …
May 11, 2013 Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has adapted to the …See details»
Transition Scores Rights to Develop Lilly Osteoarthritis Pain Drug
Jul 24, 2013 Transition Therapeutics is in-licensing TT-601, Eli Lilly's small molecule transcriptional regulator for the treatment of osteoarthritis pain.See details»
Lilly considers taking the plunge on a next-gen GLP-1 drug for …
Feb 1, 2016 Canada's Transition Therapeutics is touting positive Phase II data for a once-a-week GLP-1 treatment, triggering a decision point for partner Eli Lilly, which bought into the …See details»